Multiple endocrine neoplasia type 1 future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 3: Line 3:
{{CMG}}; {{AE}} {{Ammu}}
{{CMG}}; {{AE}} {{Ammu}}
==Overview==
==Overview==
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.
Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors ([[tropomyosin]] receptor kinase inhibitors), mTOR inhibitors, [[thienopyrimidine]] analogs and molecular [[phenotyping]].
==Future or Investigational Therapies==
==Future or Investigational Therapies==
* Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref>
* Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.<ref name="pmidhttp://dx.doi.org/10.1210/jc.2012-1230">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1210/jc.2012-1230 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref>
Line 13: Line 13:
* [[Thienopyrimidine]] analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
* [[Thienopyrimidine]] analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
* Molecular [[phenotyping]] of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.
* Molecular [[phenotyping]] of [[tumor]]s have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.
==Reference==
==Reference==
{{Reflist}}
{{Reflist}}


[[Category:Hereditary cancers]]
[[Category:Hereditary cancers]]

Revision as of 16:45, 11 September 2015

Multiple endocrine neoplasia type 1 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 1 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple endocrine neoplasia type 1 future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 1 future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 1 future or investigational therapies

CDC on Multiple endocrine neoplasia type 1 future or investigational therapies

Multiple endocrine neoplasia type 1 future or investigational therapies in the news

Blogs on Multiple endocrine neoplasia type 1 future or investigational therapies

Directions to Hospitals Treating Multiple endocrine neoplasia type 1

Risk calculators and risk factors for Multiple endocrine neoplasia type 1 future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Future or investigational therapies of multiple endocrine neoplasia type 1 include TRK inhibitors (tropomyosin receptor kinase inhibitors), mTOR inhibitors, thienopyrimidine analogs and molecular phenotyping.

Future or Investigational Therapies

  • Since multiple endocrine neoplasia type 1 is a rare disorder clinical trials are difficult to pursue due to paucity of study population.[1]
  • National and international collaborations are encouraged to recruit more patients with multiple endocrine neoplasia type 1 for clinical trials.
  • Use of TRK inhibitors (tropomyosin receptor kinase inhibitors) for medullary thyroid cancer and pancreatic neuroendocrine tumors have been investigated under multicenter clinical trials.
  • mTOR inhibitors for pancreatic neuroendocrine tumors are other subjects undergoing investigation.
  • Role of surgery for non functioning pancreatic neuroendocrine tumors is also under investigation.
  • The interaction between menin and mixed lineage leukemia protein 1(MLL1) also known as a histone H3 lysine 4 methyltransferase has been targeted to find cure for multiple endocrine neoplasia type 1
  • Thienopyrimidine analogs that binds to wild type menin have been investigated as a possible treatment for multiple endocrine neoplasia type 1.
  • Molecular phenotyping of tumors have been proposed to use to detect multiple endocrine neoplasia type 1 tumors at an early stage.

Reference

  1. Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID http://dx.doi.org/10.1210/jc.2012-1230 Check |pmid= value (help).